311 related articles for article (PubMed ID: 19877981)
21. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
22. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
Elbe D; Barr AM; Honer WG; Procyshyn RM
J Psychiatry Neurosci; 2014 May; 39(3):E32-3. PubMed ID: 24758945
[No Abstract] [Full Text] [Related]
23. Trends in antipsychotic use for youth with attention-deficit/hyperactivity disorder and disruptive behavior disorders.
dosReis S; Saini J; Hong K; Reeves G; Spence OM
Pharmacoepidemiol Drug Saf; 2022 Jul; 31(7):810-814. PubMed ID: 35484637
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
Barzman DH; DelBello MP; Adler CM; Stanford KE; Strakowski SM
J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):665-70. PubMed ID: 17201610
[TBL] [Abstract][Full Text] [Related]
25. Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics.
Rodday AM; Parsons SK; Correll CU; Robb AS; Zima BT; Saunders TS; Leslie LK
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):90-3. PubMed ID: 24679174
[TBL] [Abstract][Full Text] [Related]
26. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T; Hirsch L; Gardner D; Gorman DA
Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
[TBL] [Abstract][Full Text] [Related]
27. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
28. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
[TBL] [Abstract][Full Text] [Related]
29. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
Magalotti SR; Neudecker M; Zaraa SG; McVoy MK
Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142
[TBL] [Abstract][Full Text] [Related]
30. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
Blader JC; Pliszka SR; Jensen PS; Schooler NR; Kafantaris V
Pediatrics; 2010 Oct; 126(4):e796-806. PubMed ID: 20837589
[TBL] [Abstract][Full Text] [Related]
31. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
32. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder.
Bali V; Kamble PS; Aparasu RR
J Manag Care Spec Pharm; 2015 Jun; 21(6):486-98. PubMed ID: 26011550
[TBL] [Abstract][Full Text] [Related]
33. Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Blader JC; Pliszka SR; Kafantaris V; Foley CA; Carlson GA; Crowell JA; Bailey BY; Sauder C; Daviss WB; Sinha C; Matthews TL; Margulies DM
J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):236-251. PubMed ID: 32007604
[TBL] [Abstract][Full Text] [Related]
34. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K
J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacotherapy for conduct disorder in children and adolescents].
Levy T; Bloch Y
Harefuah; 2012 Jul; 151(7):421-6, 435, 434. PubMed ID: 23002695
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
Wigal SB
CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
Mosheva M; Dar N; Rima Madi L; Weizman A; Gothelf D
Int Clin Psychopharmacol; 2020 Nov; 35(6):300-304. PubMed ID: 32694317
[TBL] [Abstract][Full Text] [Related]
38. Medications used in the treatment of disruptive behavior in children with FASD--a guide.
Ozsarfati J; Koren G
J Popul Ther Clin Pharmacol; 2015; 22(1):e59-67. PubMed ID: 25715382
[TBL] [Abstract][Full Text] [Related]
39. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
40. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
